0001437749-23-008871.txt : 20230331 0001437749-23-008871.hdr.sgml : 20230331 20230331171221 ACCESSION NUMBER: 0001437749-23-008871 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230330 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review FILED AS OF DATE: 20230331 DATE AS OF CHANGE: 20230331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SAB Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001833214 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 853899721 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39871 FILM NUMBER: 23789094 BUSINESS ADDRESS: STREET 1: 2100 EAST 54TH STREET NORTH CITY: SIOUX FALLS STATE: SD ZIP: 57104 BUSINESS PHONE: 605-679-6980 MAIL ADDRESS: STREET 1: 2100 EAST 54TH STREET NORTH CITY: SIOUX FALLS STATE: SD ZIP: 57104 FORMER COMPANY: FORMER CONFORMED NAME: Big Cypress Acquisition Corp. DATE OF NAME CHANGE: 20201120 8-K 1 sabs20230330_8k.htm FORM 8-K sabs20230330_8k.htm
false 0001833214 0001833214 2023-03-30 2023-03-30 0001833214 sabs:CommonStock00001ParValuePerShareCustomMember 2023-03-30 2023-03-30 0001833214 sabs:WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShareCustomMember 2023-03-30 2023-03-30
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 
FORM 8-K

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 30, 2023

 
SAB BIOTHERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
 

 
Delaware
001-39871
85-3899721
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
     
2100 East 54th Street North
 
Sioux Falls, South Dakota
 
57104
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrants Telephone Number, Including Area Code: 605 679-6980
 
(Former Name or Former Address, if Changed Since Last Report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange on which registered
Common stock, $0.0001 par value per share
 
SABS
 
The NASDAQ Stock Market LLC
Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
 
SABSW
 
The NASDAQ Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


 
 

 
 
Item 2.02. Results of Operations and Financial Condition.
 
On March 31, 2023, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) issued a press release announcing its financial results for the year ended 2022. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
 
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
 
Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.
 
On March 30, 2023, the audit committee (the “Audit Committee”) of the board of directors of the Company, and the Company’s management concluded that the Company’s previously issued audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “Prior Year Financial Statements”), and the Company's previously issued interim financial statements included in the Company's Quarterly Reports on Forms 10-Q for the three months ended March 31, 2022, the six months ended June 30, 2022, and nine months ended September 30, 2022 (the “Prior Period Interim Financial Statements”), should no longer be relied upon as a result of the following accounting errors:
 
 
The Company concluded that it did not correctly account for a financed insurance premium whereby a third-party lender prepaid the Company's annual insurance premiums to our insurance companies in exchange for a short-term interest bearing note (the “Insurance Financing Agreement”). The Company previously recognized, on its consolidated balance sheet, a current prepaid asset for the amount paid by the Company under the Insurance Financing Agreement in excess of the total amortized value of the prepaid insurance policy. The Company reassessed its accounting for the Insurance Financing Agreement and determined that the Insurance Financing Agreement should be classified as a current note payable with the full amount of the insurance premium recognized as current prepaid asset at the time the Company entered into the Insurance Financing Agreement. 
     
 
The Company concluded that the Insurance Financing Agreement and corresponding payment to the third-party lender constitutes a constructive receipt and disbursement of cash. As a result, the Company determined the cash flows from financing activities contained within the Prior Year Financial Statements is understated—this error is accompanied by a corresponding overstatement in cash flows from operating activities due to an understated prepaid asset.
     
  Similar to the above assessment, the Company concluded that the cash payments to the third-party lender should be presented within cash flows from financing activities. As a result, the Company determined the cash flows from financing activities contained within the Prior Period Interim Financial Statements are overstated—this error is accompanied by a corresponding understatement in cash flows from operating activities due to the derecognition of the previously unrecognized prepaid asset.
 
Accordingly, investors should no longer rely upon the Prior Year Financial Statements or the Prior Period Interim Financial Statements.
 
The Company is restating its financial results for the fiscal year ended December 31, 2021 in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and intends to file an amendment to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 to restate the Prior Year Financial Statements.
 
The Audit Committee and management of the Company have discussed the matters disclosed in this Item 4.02(a) with Mayer Hoffman McCann P.C., the Company’s independent registered public accounting firm.
 
Cautionary Note Regarding Forward-Looking Statements
 
Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, the timing of completion of the restatements and revisions and any anticipated conclusions of the Company, the Audit Committee or the Company’s management. Other factors that could cause our actual results, performance or achievements to differ materially from our expectations include: the ongoing review of our financial statements, accounting, accounting policies and internal control over financial reporting; the preparation of, and the audit or review, as applicable, of restated filings; and the subsequent discovery of additional adjustments to our previously issued financial statements.
 
These statements are based on the current expectations of the Company and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond the Company’s control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause the Company’s or its industry’s performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in the Company’s most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other filings with or submissions to, the SEC, which are available at https://www.sec.gov/. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
 
Item 9.01 Financial Statements and Exhibits.
 
Exhibit Number
Description
99.1
Press Release of the Company, dated March 31, 2023
104
Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.
 
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
SAB Biotherapeutics, Inc.
       
Date:
March 31, 2023
By:
/s/ Eddie J. Sullivan
     
Eddie J. Sullivan
Chief Executive Officer
 
 
EX-99.1 2 ex_495726.htm PRESS RELEASE OF THE COMPANY, DATED MARCH 31, 2023 ex_495726.htm

Exhibit 99.1

 

 

SAB Biotherapeutics Provides Company Update for Full Year 2022

 

 

SIOUX FALLS, S.D., March 31, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today reported financial results for the full year ended December 31, 2022, and provided a company update.

 

“I am pleased to share the meaningful progress SAB has made this past year advancing our groundbreaking, proprietary immunotherapy platform, a powerful approach and the only one in the world that generates targeted and fully-human immunoglobulin antibodies without the need for human donors. We continue to use this platform to create first-of-its-kind approaches and set new standards in developing differentiated treatments for a myriad of complex diseases. SAB’s clinically validated platform has the potential to deliver new treatments for patients with unmet medical needs, including potential for a highly desired disease-modifying approach in difficult-to-treat chronic autoimmune disorders, where we’ve made tremendous progress in our type 1 diabetes program. Our Clostridioides difficile Infection, or C. diff, investigational product is the first and only to deliver a multi-targeted approach to the entire complex lifecycle of the C. diff pathogen. C. diff is a devastating disease recognized by the CDC as an urgent antibiotic resistance threat,” said Eddie J. Sullivan, Ph.D., Co-Founder, President, and Chief Executive Officer of SAB Biotherapeutics. “Our focus remains on enhancing patient outcomes while also generating long-term value for our shareholders.”

 

 

Pipeline Milestones and Updates

 

SAB continues to execute its strategy to build a proprietary immunology pipeline addressing complex immune disorders and respiratory and gastrointestinal diseases that disproportionately affect immunocompromised patients, including the elderly. Below are some key highlights and milestones from the year 2022:

 

 

Advanced our SAB-142 type 1 diabetes program and completed numerous pre-clinical activities, including an IND-enabling GLP toxicology study, which was completed in early 2023. 

 

 

Expanded our pipeline with SAB-195, a new, differentiated research program to treat C. diff, a potentially terminal gastrointestinal infectious disease with few effective treatments.

 

 

Announced new clinical data for SAB’s Influenza Phase 2a challenge trial, validating SAB-176’s proof of concept in reducing viral load and improving symptoms of influenza, while also reinforcing the ability to generate broadly neutralizing antibodies to H1N1 pandemic strain as well as all tested viral variants of influenza A and B.

 

 

Presented new pre-clinical data for SAB-185 demonstrating the therapeutic candidate to be effective against the majority of SARS-CoV-2 variants, including Omicron.

 

 

Announced results from a project collaborating with global biotechnology leader CSL (ASX: CSL), confirming that SAB’s DiversitAb™ polyclonal platform can generate functional and fully-human anti-idiotype polyclonal antibodies to effectively target and neutralize autoantibodies associated with autoimmune diseases.

 

 

Forged an exclusive manufacturing services agreement with Emergent BioSolutions Inc. to provide contract development and manufacturing services to produce SAB’s fully-human IgG antibody products. 

 

 

Welcomed Alexandra Kropotova, M.D., to be the company’s new Chief Medical Officer. Dr. Kropotova brings to SAB more than 20 years of experience in all phases of global clinical development, translational medicine and medical affairs. Prior to joining SAB, Dr. Kropotova was the Therapeutic Area Head of Global Specialty R&D at Teva Pharmaceuticals, where she led innovative drug development focused on delivering on a broad portfolio of immunology, respiratory, and immuno-oncology assets spanning from pre-IND to BLA/NDA filing of biologics and complex drug-device combination products and was instrumental in clinical development of Dupixent at Sanofi.

 

 

Announced the appointment of Rear Admiral (RADM), retired, Scott Giberson, a former Assistant U.S. Surgeon General and two-star admiral with the U.S. Public Health Service and current President of AMI Health to SAB’s Board of Directors

 

 

Negotiated settlement with the US Government in October 2022 and received first payment of $8.6 million in November 2022, with a second and final payment of $8.2 million in January 2023, to close out work for manufacturing of SAB-185, the company’s clinical stage therapeutic candidate for COVID-19.

 

 

Raised $7.9 million in a private placement of common stock to advance our pipeline of first-in-class therapeutic candidates and fund working capital.

 

 

Presented an overview of the Company’s DiversitAb™ Platform and data showing benefits of fully-human IgG antibody products derived from cows vs. human-derived plasma and highlighted data on SAB-176 for seasonal and pandemic influenza and SAB-185 for COVID-19 at the 2022 Plasma Product Biotechnology Conference in Cyprus.

 

 

Presented “Novel Biologic Therapeutics for Infectious Diseases,” focusing on SAB-176, a novel pan-influenza immunotherapeutic, SAB-195, an immunotherapeutic for Clostridioides difficile Infection, and SAB-185, a broadly neutralizing COVID-19 treatment, at the Pharma Partnering Conference in Boston.

 

 

 

Financial Guidance

 

 

Financial Guidance: Based on its current operating plans, SAB reaffirms that it expects its existing business plan, cash and cash equivalents, and anticipated cash flows will be sufficient to fund its operating expenses and capital expenditure requirements through December 2023.

 

 

Cash Position: Cash and cash equivalents were $15.0 million as of December 31, 2022, compared to $33.2 million on December 31, 2021.

 

 

The company reduced its annualized anticipated net cash consumption from $60 million to $18 million.

 

 

Restatement of 2021 Financial Results

 

The Company will restate its previously issued consolidated financial statements for the fiscal year ended December 31, 2021. The Company determined that it is necessary to correct the presentation of a financed insurance premium resulting in offsetting increases to current assets, current liabilities, and the associated presentation on the Company’s statement of cash flows. Investors should no longer rely upon the Company’s consolidated financial statements contained in its Form 10-K for the year ended December 31, 2021, and the Company's previously issued interim financial statements included in the Forms 10-Q for the 2022 fiscal year. The Company will restate its prior period financial results in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022. Such restatement is an error related to accounting presentation; as such it will not result in any net increase or reduction in the Company’s income, nor adjustment in historical or anticipated cash flows.

 

As previously disclosed by SAB in a Form 12b-25 filed with the Securities and Exchange Commission on March 31, 2023, SAB has delayed filing its Form 10-K because SAB and its independent auditors require additional time to complete procedures surrounding the restatement of prior period financials.

 

 

About SAB Biotherapeutics, Inc.

 

SAB Biotherapeutics, Inc. (SAB) We are a clinical-stage biopharmaceutical company focused on the development of powerful and proprietary immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders. Our development programs include infectious diseases resulting from outbreaks and pandemics, as well as immunological, gastroenterological, and respiratory diseases that have significant mortality and health impacts on immune compromised patients. SAB has applied advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™. Our versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, fully-human polyclonal immunotherapies without the need for human donors. SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit: https://www.SAb.bio/ and follow SAB on Twitter and LinkedIn.

 

Forward-Looking Statements

 

Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including the development and efficacy of our influenza program, C. diff. program, type 1 diabetes program, and other discovery programs, the likelihood that a patent will issue from any patent application, the results, including timing, of the development of SAB-176, SAB-185, SAB-142 and SAB-195 (including any IND filing or proposed clinical trials), financial projections and future financial and operating results (including estimated cost savings and cash runway), the outcome of and potential future government and other third-party collaborations or funded programs (including negotiations with the DoD).

 

These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

 

CONTACTS

 

 

Investor Relations:
SABIR@westwicke.com

 

 

Media Relations:
SABPR@westwicke.com

 

 
EX-101.SCH 3 sabs-20230330.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 sabs-20230330_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 sabs-20230330_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Entity, Ex Transition Period Amendment Flag Entity, Central Index Key Class of Stock [Axis] Class of Stock [Domain] CommonStock00001ParValuePerShare Custom [Member] WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShare Custom [Member] EX-101.PRE 6 sabs-20230330_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
Mar. 30, 2023
Document Information [Line Items]  
Entity, Registrant Name SAB BIOTHERAPEUTICS, INC.
Document, Type 8-K
Document, Period End Date Mar. 30, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-39871
Entity, Tax Identification Number 85-3899721
Entity, Address, Address Line One 2100 East 54th Street North
Entity, Address, City or Town Sioux Falls
Entity, Address, State or Province SD
Entity, Address, Postal Zip Code 57104
City Area Code 605
Local Phone Number 679-6980
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company true
Entity, Ex Transition Period false
Amendment Flag false
Entity, Central Index Key 0001833214
CommonStock00001ParValuePerShare Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common stock, $0.0001 par value per share
Trading Symbol SABS
Security Exchange Name NASDAQ
WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShare Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
Trading Symbol SABSW
Security Exchange Name NASDAQ
XML 8 sabs20230330_8k_htm.xml IDEA: XBRL DOCUMENT 0001833214 2023-03-30 2023-03-30 0001833214 sabs:CommonStock00001ParValuePerShareCustomMember 2023-03-30 2023-03-30 0001833214 sabs:WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShareCustomMember 2023-03-30 2023-03-30 false 0001833214 8-K 2023-03-30 SAB BIOTHERAPEUTICS, INC. DE 001-39871 85-3899721 2100 East 54th Street North Sioux Falls SD 57104 605 679-6980 false false false false Common stock, $0.0001 par value per share SABS NASDAQ Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share SABSW NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?2 M0$3;8T.P6BP^0"X99K>]9!:G7&BN"^)]NK+NY *W3"W\RQ+ M50/>I"MJ(-.)_#1EZA$VY8<1(86>Y4)88TS<;_3\1C0>09:'[L#TA(XA+@W# M"CT MN*+N@U6/@24DM0H#E>QV3N7TR@ZN6>1>9!CG*(.XLH/P4:V%&@/8-SF0!)?D MJG547>EYIM[IFB MG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6 M<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ B8E_ M5F60>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O M$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1 ML.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3K MU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY8 M4(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F," MJ;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R M]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]> M?P%02P$"% ,4 " ")B7]6!T%-8H$ "Q $ @ $ M 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( (F)?U:[W43*[0 "L" M 1 " :\ !D;V-0&UL4$L! A0#% @ B8E_5KV0O>)*!0 AQ8 !@ M ("!# @ 'AL+W=O7!E&UL4$L%!@ ) - D /@( .T4 $! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 3 23 1 false 2 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.sabs.com/20230330/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports sabs20230330_8k.htm ex_495726.htm sabs-20230330.xsd sabs-20230330_def.xml sabs-20230330_lab.xml sabs-20230330_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sabs20230330_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 26 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "sabs-20230330_def.xml" ] }, "inline": { "local": [ "sabs20230330_8k.htm" ] }, "labelLink": { "local": [ "sabs-20230330_lab.xml" ] }, "presentationLink": { "local": [ "sabs-20230330_pre.xml" ] }, "schema": { "local": [ "sabs-20230330.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 31, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 2, "memberStandard": 0, "nsprefix": "sabs", "nsuri": "http://www.sabs.com/20230330", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sabs20230330_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.sabs.com/20230330/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sabs20230330_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity, Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "sabs_CommonStock00001ParValuePerShareCustomMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommonStock00001ParValuePerShare Custom [Member]" } } }, "localname": "CommonStock00001ParValuePerShareCustomMember", "nsuri": "http://www.sabs.com/20230330", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "sabs_WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShareCustomMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShare Custom [Member]" } } }, "localname": "WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShareCustomMember", "nsuri": "http://www.sabs.com/20230330", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.sabs.com/20230330/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001437749-23-008871-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-008871-xbrl.zip M4$L#!!0 ( (F)?U:)&*@V8A8 &9E - 97A?-#DU-S(V+FAT;>U= MZ7,;-[+_'/\5>$Y>8E=Q*$N.#QU1/>JPHHTM:R5EL_MI"YP!240S@S$P0XKY MZ]^O&YB#%&4[:V=]%+=V2^8,!F@T^NY&[]ZDS-+]O8F2R?Z];_9*7:9J7]W\ M^\?M)\^VGO;Q=F_#/\3;_XDB<:)R966I$C& M>+RYL?5HZ[%XMK/Y>&?KB3A_):)H?R]3I13Q1%JGRI_N5^4H>GX_/,UEIGZZ M/S(VDV64J%+%I3;Y?1&;O%0Y1IWX2'>&YID+EPY3_GS MO(R<_D/M;#XJREW^.9*93N<[/USI3#EQIF;BPF0R_V&WD$FB\_'.(YV+_J;. M=VG6HIXJDW:L\QU!\XA2W9213/48#ZP>3_"H74KP6J*[F/C^367*W:4E_4,L MLT=C%V"NO[L%94_PDYYPRNK1K64QUW#_^&:BA[H4V]O]S;V-X?[>!HW"GV+_ MWOOL*%6CSVA#W^=#5^S>L8>WG^BJXY]*JV5>[N1$6>EN0 *];I>Z>XVE)=YG MA0YF8Q"NLMTU^:4&QV#\XZ<,! [PA\ ]C#?7"+>%&EJ?B7DE: X;;\\7]:G'W^Y_)[Y4H]FB\N>GGZ M^M=_BA>#ER\O>^*R?]3OB5?2QA/Q>+,G6)@].'GY^N!8G!W_=OG;Z<7Q0X@T M#^FJ\WMP)ETBW^P(O+SM3*:$_GPL3&7%V!KH]:%5\AJ/>C1%837T MM)W?08-$TX69*4LKR@(?2/ .G0M!8W*0(G2W 'G1[YFQ:>+)=AS,"=>0*G_U M%OILZ>S=9-87ORFV(71>*<)0Y>JM-\QC1(R-EB T;5T9F5&D2Q=AXTFS$2Q% M0,%LP3(SG#%^29LXVD^BP)FF(-0E>C12%L)=LWU4TK09?GI:EB*;XY 3849, MH:FZP1>.#@]PXG#H4#>?[;I&. !I4Q!!PK,U -,1TH:9ETOB&&PA4:F>@B<( MO*5U"UEJ_L&BI,IA;X$\$I8RA#3PHL[CM")KJ#.I!YFD!L" )M(60 1XHPSX M'\WI@^:L"178OX[!O%%I(H8"UIXUV(N056GX'!7-82R,1A(3H")0@PH[GZI MFU8!_,14KB5>3$^46(V7AZEQI=6)-JPZ/3@Z5>(T M'WF#LB>PJ\,^OZ)M3Q68:RSIE4R#""V%]@AF>N"#9_KM8!E'B5WJJ"79&@L8 M1)\2#JUJCCG56!]R4M'9T_L IW-Q( %^LT3K"V)IL"9 (N)BE$.L1B;<0ZI MP88W3W)T2.(8Q%X!C+STG %%!'P#9YK(-"9RIY/HL\GGK4_W M.=B7?X7M!^JME80C%E9,XU!7D)J0*-CZF/E_6.F4#(S;^C U&%'4V(-K24*+ MZ+86 \&1]WZMYE[8DW_KH?A?A;=O MMY\^V_:(HV7>#[RWP?0?\-L"1 .V+$&1)*W!:='FCUMWJ7$F.\\QI%7S*E/6 M6P$JJHTB(:')I[ID/Z.E;6C!T[.C2.6@%?I]\O(<''NC8\^:KJR2.1D<&DIZ M!JW9K.+/$>8%*!L,1:Y>OT-]'23B+Y'$/?PE@EQ3_YKZWPG1\0T\T210?Z,? MV!)G7MA^0IX3K/;>LO< W: X %'S!IF6;%,W]JMLS76R3V$/6T^!X? !V&W&@L6)3F+\%8K M]B^F,+!2N _2!Q9TQH$BO'#SK"A-YNA#70/0Z[H?5N&YL7%M.\FA3G7)EF = MMA!#^'T)N"^'UX.%]!]>&34A"HS]>?-L4[ 8R."9D3VI.8XV _6R X<_Q*M ME0'E M2_%@; M%H*U/D"]9L36"2U]9MLF4G6I*8LJQ590$ M*#U%'F?*A[@/M+DT:44,0F9CW">"#ZD_CN%9S%7G9#(?%$_N6L1_2EG3!<[M MLMSI^*3FKGF='W#K^,":)3X22_RF4LIZ)&*0JAN0JI7B%PKQEF8*7^05IV2\ M845F5$AL-Y1*QIO/RKP*";V0D^F+(_ROF0E>"@Z?"9YBW9GA+#'(>^L11W39 MTU WA;):4H/#[R*3:L'?6!/][W6!^+[B:]#*"3^J-"*A910D%'"%OG6T1LKU/SXX( M)0C;4.>.^$4\\F)!(YK>M M:%L[7LNTC6M\9R9JBJBFI:_.QL01 (_,EY-4PA4"!+4@K">EO \U=E*?S:IKT)SL&K MTWJLEYZ-\#TPTK(X.@+,,=C>K9EFS30?RC1G:FQ"!@#:HDP[1C"3\*4X,0 I MY\>0Z:]!>50,1SG9D%..%=16$LI7"CFO6>Z[Y_VGE-1-25G@TS-,E-7?]NI* M0Z=@1H+,ZPU9WA;["K*0=.23.V4^"/.D6E'%3B=*4%RI MM]*B:524KXM<'6FB:0]?_^/T*-K<7FNJ-=-],--=2*Z9^.Y9?[M+WA0GTE.B MN"*%-5ES 6@VPP!7FOB:B-[73JK%%!_&^7I"G4=Q"M-O-2V[$.0ABPTF.J,5==A+@D>^^(6)[784JB5,X.N(F9$:4.876- MM,]3O3-H J?#>KU$;D]L9DY,X1#R%U']#GSF,LDK-<5(*JP*E@N)/U8 %)=L MHJ1-=JU-E]'C.H7151CDY-#N66&>^_7.0^'GP4+0]]#DG)#W#O'AO+#5.@ZZ MYLJ/R96A1/:,;W<;6")@C M:OFB6[_/2_0ZE2CY[=>>>=ZCLKK#<+TZ6K*<&&^8L"DVZ=7\Z&,VXES:,O=! MET7^.S!4B_BY\%^BIX+5^D_WST\.?EGB+\$,)OSG$5VP"_?NPA.^1,B/Z-+A MPEPOKBZ:R;JW],)E,M%98.G;R2BR9G;[(4D"<7YR]NNK=@\807K$>"O*?Z'V[]Z??A2Y]=O14"#AY7T\Z>O M,M:'?<>-RT]7X_VBN6EU4L$&!7O]E\NZU[KK"]9=MZEG1QS($#$G6[".HIFB MOKH!HRYWK&4$I/Z(,N:AH%V7G'4@ZY ^53?:\1=#4F9TZX<^[<$CEW^8Z+*R=/4&2_*=I)( AQ@;3]IKB%PQ_)FHI35K?<&L=4BT>V[@@<&> MVA&'=U&]F%$RZ[O-)_U'3;1"LA.VXFHL!]BLOQ[ZW>/'G?@=_KL\?G--QVLZ M_F ZOFKCNKX,5WF)*_.\XOJC19&=J]*3>&QR5V4%YS(Y2/#=TY; B7PWG]<_ M/Q*!Q=3KO7 ML/0/JPB"[MM8G:V&P)P!H(@+ $01_;R#@>&2'5A9I8@5%4B$-5>R85^?O)L\MRK/'DWIYGWGD>^?*6L/'X_L=&"'C&#Z^M_H[ MQ+!+]HFC.73IMY*;,L#*B99\SFJ@ID+!LU)(-F1B5IT[!IM,]3 5I?J)I^N< MZ$03(7$:D=ZM= ^^Q*X@B]45"T28X!0I]\K- MPN:E E"%$0%9CB#5 MUQ#LHK9:S1&?_J _4V)Z#W-@,*1,_HK>#CTNO?U*#8$[]^N[-U%'&;HU_R=Z M.'5J"HENEZKOVK8YOHO1RDX[/A3?*?EO;P2TA?_^>JB?!FNP,%R^^>G:TD1? M];2J,XMOI]*%,UQ";339RIE;XX+-=Q /MQ!R"RDZ,AW:NV]- 24AK!>NKG*H MNWVXW"EAL2G"1$Z5<#A-[GD%4#/N0TB7C3B-Z&NW-$Z"PDPFK_>^JEE"OQ%P MLBA238Y*?7N=[F?0$:@A+&OG>4V,8PX<46%L=0!)S/.4';R MP57\4!S0]4,54JP>TY1W!0AP>6_E8-M;(CI %;-O3,J6HN$0@RRW04@4AZ;S M\"U^N+4/:T/?#ZGI-'3:Z166RQ(&(G#\IYN&=4BQ2Z?OV96).VYXJQ+K<5,J MHAR(_-L5N0WI<5>:F9R'8MCFY@Y=!>@62(W; BENJN&KA5?RIB:$O* J)2J) MYMN>66.^9\8;PR17@**E! M$-Y0PD$EI_DG5T!_41K!X"QL$KTTALM6+AMK]RO5"X?*DA?1->NY6Q65EK.) M2K(75$2F;<<"';'

C@+$T8&S)5RPJ6YA0;T^4[.0(DTL[I'=TP\4QI3,7 ML&]P'HJ3.J;<2UVWLX+-SU)C$+.2V=S>?L*4?A<$_OX9<3\KM[CF#S8H9X:: MG;$!#U8-2>NA@H2 M>7)K?LXK+#_UKN4M^%8]Y-3#\C-+]QENS=IT8;BUG%+9BF?7R\]&%>49EI]" MAM)!U4^Y YT&=9.C=E-P@R$BB-#]D2$C?P>F-@B/;Q)R]H(M 4=O8!_DB?]7 MEU@[5 !*Z9 NSJ=D:P#4YMY*O\$JZ(EAU?&6]3L,IBSXD4QKQ1-+XR-=77 M(/"),2$*(\E*\+6X,%W8Z0^W26'AA5=!/_MZB."BD#N^L#>=<4_%P.5+QF!3 MO-%44M0M($X0(L$Y"O M0.2C: @1V#)I@BB=?@HNB'+[G%-0B86.HYE1=3P*,;ZN:M$\JFO < MY#0SD+9QE?G^C1[TIK4F2_@,#.YT< -JI51'*:E7)$$68.T"1T#XV P!$#HH M0E_@N&P;6&N$UL+)$^KC"6G\D ?G6XDD :SO/]3T+ZJ[Q=%5@&[PS;>M?*LB M 3+ V-8+9N5BJXLZK'W7GNCR_)#FY,2^)WA7B[98\O=MI=T%9A$O_,G4BC6T M%LU(C-'M"19"'#>UM^.F/:()I]Y4-.P-:+>D=GIAI.L._7M7RWCQ'*015:]6 MPQ!FD;^H['88>T.[?P]$?WKQ M?S.\G^GX6O5AJ'SJ'7\A6*5+Y_(.E)Y_.I1VZC]?#BZOHK::=66U[4>MHJV+ M2/$/B@J"/_G_7^7_ 5!+ P04 " ")B7]66-4D\=L# !Q$ $0 '-A M8G,M,C R,S S,S N>'-DS5=-;]LX$+TOT/^@U5VF%&\*V(A3!$E:&$@:HTYW M]U;0U-@F*I$J/QKGW^^0DFPID1/9W18]B2+?X[P9#D>CLW>;/ N^@])1Q?SR^DT#+2A(J69%# )A0S?G;_YX^S/*/H A0UD :+ MQ^!^;44*ZDKF$,RD,C0+HF!(A@DYB4^&P6B!BXF8%4*]P@'A(NG H&88W7:0O],*RQ"?GW]F;N M]]Z",RZ^=L&3T6A$_&H-%5((FW<+28TBYK$ @J (4: XJWG:%&K+\@P-;+"2 MWXE;<4%(:N@S,6U/W?*"ZJVG/>2TI3A :MIBJMU/2;E80U/@W:)QP6O^]E<- M9=(*HQZ[X=5BRTW-V9Z <-8",JL4IMV^K:O5%@4V;-T-=RMM&72A6_%S$P,F MF5(OE5(RY_T.^/ZLB/7.Q)CBSI\<$NUF.>D5[1W##J!P>8[E=V7K9;E+J MET/.>T^Q[)=E%=P-CK;YI.3V<[K)V;X=+:%1QGN9W^+]J&VV,DR%D,;O44NA M1<'%4KI7]]$=UU_>3[ ,?%,PIHJY\O5RZT *)0M0AH-N?KS]!FL%RTGHO@!1 M7?V_9'0QP&]3#7EFH%W%??E$"F0W.WDUU]UIW!YCFD$9XE_I2 K+0QU!"A?< M'<)OYTVAX%!OD**Q*:"'^>.H][@4<&QA\>ML?&<1I9)9/\!F.\(G-X^12T^5 M^_W#P/$^?YJ^W%N4POKONE6U.YFR<>K3H9['<8QM_E5EHSF\$&EP[B7,_9C1C-MM&M2)5B"Y".ZM>QS\]MV<,TCHH/_.D8)#NDE*U MB0$>BU&489-HE,6T\T>-DU_J &%\RO!,FT?LJN(D? 7#,RP'+CG+K;5%6]Q8 MM_I!25M,0O\S->:8 MB9^B0L9U 3_MI-<=ZYA6GJ9_&2<)G>>UQJ56F&]/;H M4N:Y%',CV5=,ASB94?4WS2S,0,W75,&EU4;FMY O0-4>'L@YQN/R1VZP3@$PP4 &@W 5 &ULU5M=<]HX%'W?F?T/7O?9,0Y-=\.4=AA".\PF MA0ETN[,O&6%?0!-98B4Y@7^_DOD(*98M"/9X\T",="R=HX^KJWN3CY^7,7&> M@ O,:-L-+AJN S1D$::SMOM]Y'5&W7[?=81$-$*$46B[E+F?/_WZR\??/.\K M4.!(0N1,5LYXGM (^ V+P1DR+A%Q/*?I-P/_LG'9=*Y;0:,5?'"&=YZG7R>8 M/K;TQP0)3NA7WP ME;^NW$$/FGYNIMC@^OK:3VMW4(&S@*K1P/_[[G84SB%&'J9Z3$+-1>"62 MO M68AD.I"%$APC0G_SMC!/%WG!I=<,+I8BWPZ?ZO=,_O]MZ4JX5:!@+'"P*N_U9*$8L1IEX, M\03XB>0RVS@S31P#U;O$6W=V*E-#,^M\3"9@+?K[T2^.2V5-KXP10F1 M;Q_@U^T8Z&ZY_DQ4]R301%R$+$X-6*/9;/@I5;7Q):A>I)K#,$D?E'7TU&\L M5\HP3!F/4SOP6H)NS=NVE'(]NB&#!J444ZR!M^KK!JNIEJ)F30*6$I2YWS-) MA(4'4R:V4RX@O)BQ)S\"K/L/_GVO'[WUXWKB #_TTDYO7NT,@B9 VJZI>LV& M:,O+^-Z85,LF>[&5PNIF,TO]EYD9HPF!#(9%T&I9JK4)?;74A!W3 WB);&]A MALAZ/CM+G$70@*A@!,>JBYP1VZ^N@,T0.&91CT8WRFKDT,K$E;Y7[V&&A>2( MRF\HSJ*7!RN=75\YUGS!>+J\1]KL=EE")5]U660F:_56Z=R_8 +?DGWWZH#H M(:1T5F.T[$?ZI)KBM>==0+$ 7SK?3A1Q$&+S2UNXP,@U!UL5SZYZ'/ Q>S8? M?T9D51S3'3'@0\Z>\/HZEDO4 *^*[9 I=XO\@Q>Y6SX/7")3/8D=#LC +:NZ MS#-9-4J&PD0M MNE5P.1ECF7D?,$%*9#7F2,<21ZMXPK*68F9]!:/46X9S1&=@\!/S8*6?%;T8 M^$P-RE?.GN5WSFXD:H26R[*CM&.DM^86@ M60:US/K21ZVK.N2(])5]6/X)YKDUX$[B-T5BDH;-$N'-$%JD)'T@4FQ+4JY> M(]@$F]]MBA]&VPA1ER A!M.19.%CQCW9&E\Q_WT:F=&<8N#_A_&ID:B,Z*0J M>="GFKYVJO8;ZB<8(OX7(@FH#3R:(W7J)4*R^ XR/+23WW\CY1^(ZZN]Z*%P MWEL"#['00:\OC \HI)T.IGNT.K)#-S 8"LD3$#4=B5/=D?7)MA^>K9CREF<'Q!C1:%:U461B.#L(E[O MB9-49&\L"S6754R)O>UE]O;.0ERSDJDZD[K\*:QB7^6DTUX696'8GEG$I*O; M9F?3=*3_4.6\92:87Z_-G,W$WGP85F@TSZ*TJE/Q;6M@4\BHA*7LD73-*0$P MTP]'C]S>7TCDKOO;@\06.R9=5XNE<*JTPVQ5A0?H^>7D9+DJ/#O/IZLX/68A MZWU-91V12+-0>553E:8LG(6D#S659)6UL]#W>TWU%6;Z++3]46]MIOR@A;+K M>BO+32C:G-7E>ZAOTI>3A+115S]7Q)S&M-%3/U\D/PEJHZE^?HA%]M1&6/T\ MD:+,JXVJ^GD>MME:&W7UU;".H?GY'<5+: MYC)=5W_#(H]M(Z]^#H==]MM&6_V%GGWO9BC_Y,VU>SCIUVY M_M#_Q*5*_@-02P,$% @ B8E_5ILP'!P8!P 3DD !4 !S86)S+3(P M,C,P,S,P7VQA8BYX;6S-G&MOVS84AK\/V'_@W"\;4$56O!9(T+0PW+0PEC9& M[:[#BJ&@9=H6*O-X%-TX_WXD)3N^D+K9I-8/B2,=G??X/8]$ZM97;]:+&/T@ M+(F WK2"BW8+$1K")**SF];GH=<=]OK]%DHXIA,< R4W+0JM-Z]__NG5+Y[W MGE#","<3-'Y$H_F*3@A["PN"!L XCI&'.GXG\"_;EQUT=1VTKX.7:/#!\^3F M<42_7\L?8YP0),J@B?KSIC7G?'GM^P\/#Q?K,8LO@,U$BG;'WT2WLG"Y=L*W M&^P&O_#3E=O0H]0/'14;7%U=^6KM-C2)=($B:>#_]>%N&,[) GL1E9Z$LI8D MND[4PCL(,5=&%GX%9(R0?WF;,$\N\H)+KQ-RBF>Z;/QQ*=A(HL4R M)BW_Q#H'A$4PN:5G+EB?UD+E0XX9MU'[<>*S5C\"L=>>M^[CE.>M6!RZR)DK M/DIYUHH_DC.3<9CP7-76*),?EUBJMEC&W(E/69A,EW,056K9(7LG+5ES(D:@ MG:-D#.%1^#&#'_Z$1'*$"O[]77[TTH^J>O'GMUO*(_XH!C4F95J=5A/+P0#8X;?,3^'%NVZ5LN'87D826+$P'2:%DAS*"?4^#UNO4RWT M-57[YY7_5,Q^F5VV<0ZSL*".+,(/08R'2[[_':8,%CE609$'Z5<2$LK(,S;V M3NP]<:K;74>)IK>&B(KM/D8*\E+:1V&BC'7'T5\6D%+F0E777*(SPN.8 ME,-F+_1T9%2Z9G!1THV3LN^GF1*-4=8)&0F!'"IV5]8,X3EZ4D52MH$S!8.%4-8;RR#T:0AL"4R- M-T,N..S!BG+VV(.)F8M26]7")#>S*VKVBGB.5!D(&,I*0;*6!E JYSK4M-,R M:.^BF'Q<+<:$&:DZ#JF%T%,:5[Q(191*-H"%QC8HXX?EAH_PNC\1@UPTC=+[ M"07=+XBOA8(AIRLNA#S:UV^.DB)[H;)OEOGI3B;"XB3[)4^8 R,[.;&UN-'D M<\5,IKG]@-05CGO:Q("39RM4\LL-*SWQ\9Z-X,%\C=L8>0HG3]F<4R*EY=1$ MBC='B,9.'1\FG]S0H:8_]VS X$>4WO+.;:HA_!1.#E(ZAV4[D=U4T!PQ)G=U MV.3:YH:= 20T!XO%BF:G/[K;J[EQ%3NOS66[_9DHVE=U MBD"^AU#:'&LP#"&.PHA'=/9!S$%8A&,-">:@BA@<)[+-P),BVD@Z!2#'.BCG MB;76#QB1R!%1O[IE)Q_*8O?3J78$* ZNB((YH6TDA+(7[DBC5!LI<:=PE# 5 MJKGE"I9^DJP(JX2,<9/3P#E*ZQR?M(+_#45FG_4L%1AH;^0AX4H,?(_!Y7@4 M<>V3.J:0JJ/.01K;A"@1!%,47/XZ_@UMY-V..R;KH(PGUIH^8EB^LS)\7(Q! M-]/0KJ_8[KT4 MF2;:B+I_\"+702AKC>4+B[<+PF8"P?<,'OAG(NL_B'FP,,35VO$/\J\688+Q44/HEYLEFBV/#:0?8R];-L\3=UEU1RV8MQDMQ/AQS"[YIWPDK' M5^"E,*?UVU523YY3*D77;XR5MQ0J>^64H=U2M"^+%@?6H.8XF6M<7+](6L)& M*.]/.402/$YDWSOM3J>MNBZ7?)/7NN2CP2)W6_P+!IC]B>,5$9.7X1PSTELE M'!8?B.;69^WM*S!26<,Z.@6UH+08]#4MQQU3];L!)]M\$H%?,).O/B2W.)S? MK@D+HT2^]_8.V#TE2OA^NE-:EW=I%D8&+ K%VB!XT2[+JWVUJG3;J\CZ'>2S M5M[LGN. "W#<\,.]4GBX8^F=^/3Z:5&4_E<]8LE_4$L#!!0 ( (F)?U:F M"2H&5 4 '0W 5 &ULW5M=<]HX%'W? MF?T/7O?9&(>VNV%*.PPA':9)80+=[NQ+1M@"-)$E5I(#_/N]$A]+)I8MTC73 M. ]@K&/IZ.A*NKY7^?!IG5+O$0M)..OX4:/I>YC%/"%LWO&_C8/NN#<8^)Y4 MB"6(B N%J!=XK; 5 MA1?-BY9WV8Z:[>B]-[H- OTX)>RAK3^F2&(/:#!I?G;\A5++=ABN5JO&>BIH M@XLY5-%LA7NTOX/KTD0='C@&OPNWA0?HLZI7+8.-+B\O0U-Z@$J2!X1*H_"O MVYMQO, I"@C3FL2:BR1M:6[>\!@I(V1I%SPK0O\*]K! WPJBBZ 5-=8R\0_" M"4[Q'9YY^OO;W>!)BQ)-92/FJ=&]V6HU0XT*@:_"*68J2'B@,W M=FA-MI+^;&G@M<)@IT=:4AX_Z;%N6N[M2>*X,>>/88*);C_ZYZV^#+:71@[X M>=\WC8+I(W)HCJ(IIAW?5KQE0[7)<'&DRO_ Y@;/$=VVV5T3F4/(@JB0T]5N MC ;_C\*,;#?G$HHE^,KY=I,$MD6Y^]*K M263E6H ]%\\>7 [%A*_LVYX5>2Z.9D8,Q4CP1[+UV J)6N#G8COBX-C0O\FR M<,H7@2MDJ@>Q*S"R<,LKKM+/@4KI: %O)=9);8-4R.J[( I\&[!T 5!-(><'50ALY' 6@UX 35^_43[Z6(XF^6.;#GX M?$P'4F98G,37^DB5(X_C#(QN$UU,)T3E^MXV2(6L)@+I<,-XDTYYGBGFEI]! MI?XZ7B VQQ8_L0A6^5[13[&8@RB?!5^I!=C5$K&-=;,H1%?/=0TCR"31Z]O6 MY[<3M4(K9-F%Z9CH*7E-T3R'6FYYY:KUH$&!Z #6A_47;!];"^Y%_&9(3DT@ M*I/!'*&E(1EBJN3^CN$:-*-=/.K-[O;]>!^+Z5$DY7 V5CQ^R(D]..//S/^8 M1FX4IQSHRC@GG@9W[O7>H%_>H-XF_$4C)/Y$-,,P#<8+!'M')A5/;W&.G_/B MYW^0\GTNJK+=C \$B2&TBAZUW3M M8/6MV>0XCE-V1>QQ 7MVQV_Z'I3 SBUP0B)]%/Y]6M$.$2^@#4T&\(/2P1LX$3XO#>[PL' G5EW<\^CD[[KZV M,VKDJL()WI&CI;Q MDZY,IUB&>X[%R4Q>UUQYWE/NFJ6HX:2QJF'/=+WF_?NE*A0DUE[S-OVR*7)" M;LQ)G+=U$L>6CW-2XEV=E'!*^SG)\KY.LI1F&)TD^;V&DMC2F4Z"_%%#00K3 MIDZJ7-90E8($K9N#5A-_U9X9=I.A)HYJ<3K:38J:>*L.Z6\W/6KBKI9EW-W$ MJ(E[ZIK<=Q.E)I[J:2<(W*2IB;=:?&S!38J:>*D%QR7<=*B)"XBYL.-?%/'8[7'"5APF>20,4/'P\E^D/_ M0Q?<^1=02P,$% @ B8E_5A30F[C8& -Y( !, !S86)S,C R,S S M,S!?.&LN:'1M[3UK<^,VDI\S5?VPR]GS]86T4 M16&K6KVZNJI<-2N!.J_6=W=WJQ/LLV8ZM908YCI.!LJCKHU:;:L*K4E';'!E MVC??SS0F77TN'9WOJ853.0\NJ]0$[S3JV7'E4A":5>GKB/N.2/MKMVAET+=> M_>/;U[XS$F.>=):3J Q3YUY(0)&^)WWQQ\?>UVJDN*^'@1KS2 8^C%7?+-=V MRLT9D-#U8CE"L34S9?%J;IJO46YLI1@,?#\>%X_C1JH:34-1A4YEZ"64=)+W M8EW&IAGRAUP/Z*VDA7!?KM4SBXLC)$G"H M!<&IY<'14:B*F0=;N8S?1(R7 S#?+X)SF( M"H5DTPA)-.-C>3,?E^>Y/QK%OBN4&XQ%[NW>X>=/$M9[KBM.,,Y0=C6Z3@JU MQ0VPN$(6TPD:B$Q_;608X9SSL) /L*& *YT@]B,U+9[!-N:802WA&H4\4]^9 M8S+I+.$QZ>1&=6*EA.\L@\.VYEX1$V=4W!U; A= MRUK^1[18O19&>XP>#/E8>M,6^^FO.(CVSN18:'8LKE@O&'/?/-QC(7==X/H6 MJTF?U2IUZ>\Q((H.5(OQ. KV "FNO$QFQ$7"SG$G40W/I(CYVOJPQGZ,8 KNWVF/AN_#_Z)/'S]<.AMS3 M8K^:&^+68W9]H-6T X,J[AT!:29?Q'3MH 92N=-L-NH;BQ/ %-7Y18 -%\BD M0N,#U(DM30(-\S(R7:T1>0'(+N6$7RI@9]=L,VHZ:);CT!-(1#M+?F!ZH(-8 MV=]DUUMVB4RZLR7.6@6MI_N!>+4Z'Z(Z[$TV#6(D><(XS) M Q>FG(2>=&3T38P',(T+ NMK<&\^K%DEWUJZLC525:V;UM>)=12,S?C[U<)I M,^C.0/@6F>%WKL"+C'27.Z/N1"A' @X]\2E0)[X@=)T,,PAM1VW?=A.GH"R@ MM5[?K+T5UGE8;+Q51DL5=T9/5W,6L K&$OY]ES6:66O\\YP=_GEO9KS)=M// M2ZXD4 -L$X0XWMZ8JW/IM[!Y[>"G'R>\MF8G1B&C%@-+5?1 M?/6'GZ\&_\W,N027N? MM<^Z_?WJ )XI F)PT.]V?NL=G1UU^ZQ]?,BZ?W1^:1]_[K+.R;=O1_W^T?STZ.2^RPTJFP1FUS8Y?Z+%(O QFSH+%[8KBQ>2U!T;V[%K_7 M>X[%3F>";V81/B,I=BE8Y )#/R6Q/YWTOK';.96'@1.CMB(G']LQP)GDH?WYY]E\UR,_N> M0J 6PQLL"EA?.)@+8_4F"Q2K;ZZ[[UDP9-%(8%.L9"0!@"X$T-P_%ZSM1-A< MWVUN/#>:5QR3X00F[/UY+?@8.6% MCIBXA-Y,4;-PW[=64@PF"?EA34ZBEHLN%G0:N7PZA6&%7Z0X3LG!Z!K'@R#[ MQI4S8N"4# Y*# @86HBF_?9']O'H MY.R7;J]]VOWM[*C3+[&CXTZEF*[7K_*)##& O=Z=<- ,N$ C*\G"&->L'PH' M0Q&729\=19IUP->'5]\_BP;YOO@_PFC,0O1A#?QB1WB>3=ZEOW7(G>3W[6V0 M63JYY0:2LB>&48NR@/:!(J3:O."['][]\,-^A(G(@_U(P6_\Z2*V 1"(/>LI M%)="1=+A7D*E* A35#>;_Z3!X.6GLYVWT^RX!89Q921"%5RB<.15N]$"1[X3 M*# >M"=%\7;'9-D[@6N4PJ'P^!78A6MT **A&KDI,E=!X,;+1. \?CY)3\ + M$/L3,FJ8G=_=V:X_,#9>*#O-8^.,3XYL;LSW-S9W=UNK(@;^)?$ M[[5)(=@;DA/T6$_ 4U7L5W!4M2O)EHZA2#!#^/LNYIGH=]3KL^XX]((I9OKF")9G<'8<5):LLHB!5UYT8BGO0OT[ MOELP[VN5P3NHKK;K*J&U_>$@L>"* @!J8XY!=!Q&\(;N^LS%<7YT$01<'XM8K>:0"4\/Y/AJEK MN;E=KVV\>6_!+A]#TU,%G"5#[K'N1#AQ)"\%.QF"K1'Z0?R"^UB&IT<,L )# M7KC>OKZ#?TVX5J5X\BG#]5<4P!;3&_!< MLS/AB7 4^(DW64)/V8L1N:RM!"?F:)FWB"RWTCUH6G"45-MLU3:+=,U=QOX: M (I/$?1, +2UO5O>VMVIW4JA/2=W/ZFP?X*>$"L=4Y).,?O3ZL82DT-,S/GG MPF5]M+[L*[ID)NV]4JKNX:%^3:F[.ZS^:3@C-TMG))P+VMWA(3AD(?2,4+U. MV$!XP14R 38B;["=\ACBE M-^T+P0"(8\(WNYND9CEA*G=DW)\F;&[FII<80)Q MIO0Q@L6<^6317ESG#ZS-&Y-D[!T">-YR+,W-HP&;VP%;0%?);(J5F ;].%S< M#[A;NG,0!-X HH< UCO)*NS?E8R @S"+$?LVM-=(@]WMC8V]VR7R+%92>_RD M6+$+ 71D5\+"S*9J+P9&VFAL6DZ?VTS%/=3U^C;K?.JQ1K-6@8[O7Z1U^EL@ M'E,@^@&5M0'NOH$.!J)XKU$:9JL KC%SH:"R!Q=^]K"8GI M^[>8?/=B7^K/P%HVFP24B6 :_".7J?/!>JW$\'_O]]@-FPKU[.MWV$"X,[;NREN-6F7G67!W;$L#B;5$HJQ!UUR-)#R9*:3[[O3/ M4/I,&)#@KAV8MV&9\'J)_:-6P2%8R!6[Q$%8B$?) M1E1(=H^RJ5OP[ N3X*>BC-431BVL84UO_]DQ_CR"?P;^PR.C?=YS1MVR6&:0 M"$OB)IJ"Z^-V_[#]KWG:,)J.?>/J0D3LZ]?.=ZN.'OBLZ[7**YFKE)B(=#HD M,<,]2M)=:$2LHC-TXA'C?M(?E!Q.C)W^4:]7-FM_*[T72?\"%?G[LQ/HE>K( MAZ;2^BTD,@;>\.+3S"LT7X/(*JEJ>VQ:5FA09H.P< MT^GG*KB*1I@+"7&KE&OFBJ'TS3$:L\-4VRPXJS<[HM=DZS_]6-_:WL.2C^;N M'FTV)>_ ;$"X$,_A8#6 R:LT!N7&BL?_YL?&5,OL]UM+4OMO7H$'PVO$8 2L'VA-,F%^H(1R(KPA(/W*_D! M9;9B\ RP%Q#&5C'@57"2LEWFZ@;R,G N;XJ37TF8&JGKPW*@18E+T)?02_K< M=W"7BSMT&Q9VQONY7*Y<;>H7W&5IM>8Z3]-J69FJ/ H/3<[2-9K#HS?EAI_H MEH9K;X5XA%LH5KL5XE&$A')H']9./W_\4KS/DFLVVLQ[EWQJ9['8@[$'7%=Q_GA.?V7/M=7.HO<3H3+0,T&7BH8C!=]=4IUHI M,D4=NSQI-^U??>@Y>E8]#/'%0UEH0K,!0!< MAXK= /07> 7QBS M@A[52 YDQ'9W*W4B+578)6LP]P*F][S1F])_,8[4_>?!F$?ZZ4VL&21E[2:Y MD9:,J:RP,KN5@%C"H_N05#9GD5_"Y(#GD9\P$.!B@_M!-8Z#E(.&TA.N'29E M X S#+0@(%+[OK.B[UQ"%N!CPT7K=IILQY1;,?.!C'^%J0T=#_X-4QG4".9) M/I">F87FY1'3!I0286/YRI:SFO2A!_H]MI!SS%URN&*];+,50"R./K*K+*%_ M!AZ29X]AX SG= FFEP$&D>C!P#$_1TBHEXY!&1A@2KAQ($*Z5,"L;8 >'8D< MEJ%";#G$4V,(KS:7#CBYI64'>T/2E)B2#30E[#CPRST!S(%K!H2>HNMJ"G6/ MC.Z;24F:5-!(1@Z2Y1%+M$%0DMIO;$$EZ@EL.4(?0XZA[5**J\I;-3ZUQ/@ MNYO9.:$$*Q.P_%/D;(Q!5R=IFTFOT0:# #@??[A2@7P&2B+(]"_!DXK54V*['F!X%L8>1+O,"4,H*M2(X('CA2AS""E$+ M6S=FL> ^$\4*I8 U7UO=/04FM\A"W%C$889M[N1 O=UQOB5U9@][7&1W:WMW M[]8Y\L>%ZFPF;_/Z"A2D*TT^!LP]ZD&00\M])'GG4+GE$"1Y"M$BN230*>1R7FUPH[T6QM+H P6QRK28%!.Z+]*?%2<8 MH$"Z5%0&.1P;M8-7?@U C:'$P&+RAN H'=**+)ZC.U>"1#:1V K+HBFCW0 I MP;D/V 9W">06XQ! (E5Y&$>->S0V.,HBPN#'7(,>I0B X-KX0.:$SYAP2RV# M:18[&5?N6H@M.JS/1JHQP.O)861@+(#3%A;,8A^:+(-RK Z?5HP495>M!,*J M,:.&R\QHH03ZZP%#W>H*I IEQ%.+>/U;5E."?J1$A+F4BM1C@DFB:,BGI)(H M6"-U&7M>@DZ[UD46G5$/ARPFC84R C'+T8,R-\:P!3>OHY)3H*MM2S^<5KO5 MQMHJ5RP\ H16-]Y1(^;*75??85HL;+U&':[&XJ0I=8BQ+!Z.XU-JL3Q2H E1 M740RBB-!3(V_5.S0(7=@3R%#*SE2#R#.-O, 0SMX EB)H34$[ET%'?7&WN4"B ' MA;;)G$1CDV;C>GW]_>=I _X5HMJCGW,Z?B@U:*;K\Q#2 M^-(KI#-N'JUALO5T&)Z4$F:'T6CPY$LTB0 ]=#8%AC5($:NPTAOCC+D,&Q$A MDQO+I]/8B(.E 2?'B2G"P*8QA_= 0/&I%^@D/027/YO? J(_R48 M#F$*]LWI0"C)3BN=2JF0L'A,+11T5BU_L&8 P4\NM)%J_(;HLB\/.CQ&\\#5 ME!UCY-2C)#^N%9C["OXL?PV""_P]X\S]JGQ#*>,.^$8<=Q9F2IRV3,R6G7%F MT)QCW@.X#8P$>E)L"$;7V/FA191G$949"-5"=I^)DHY\"(-S-<"V]+(,&]"? M&;UPB3HBLR?S%?ZQEW'T!&ZZS79I=C:$N% MI_MT TP\7HI2LE]F'X_Y=/[1E?2\^6>@WR0>(Y]_CDZ5]..%YT 5B;=Y+;YA M-/3"^)-0.-'\4V.T%^ K>AAZW%]X!M(N%T<- _P.&VCEA>D@P"MX=C'_;!A' ML5I86!!'2*CD*>WS64?;;H410Q#C6 !O11F0IVU>EFB,'8"G)EU!<-S0%6B)_ MKTQF%,0&56JE.\)4.IERB6OC#-,^OPD3%1@::YF7[\M4[!6T*-'H 1(2'?(" M'8YE9YAJA+9XYKR4L.2,-K]IBPZ;1R@T::#C2CS*FUZH .)G7/:8: P<;+>\ M+8);!"+XFP%B2='.'"X.^Q=MD90R1BG[MTG7H<9(?!SEPXLH?"KP*"+)>6+H MR,!K>[/DGTJN_)GMXYA],UM!)Z[,IG"(GW3"6*"$<%H2NG9G5N^E+^MXH,5? M,5I6--P( 55:X.8 &1X/_OQWK*,4=;CFQ0VC(BR\(4ML)%'G TC\ JO+;."1 MI"-S[#/G-9&X6"FUFB/I9ODWP[:E7/?HR!.$D)@MV4PO($#%G1 MT;>!DTG"GL<LZL[)3+:D MZ@W9@*0(:+=2JR_)*@)OV=(W_3R%.Z_O1H?YU/=8NJXWJXJF0=AJ1_,?=^<= MR)^4-9H+46]_F?%+7MOA3-7?]X( NTRSRB47WCPD]%AE>BM"% &XSYGY6+28 M_+FQN[G=V,*OBJ<"@N=!RF(2*;!;+6'XP%RLHS46]5$Q\GRX8XH*\M76^U5^ M\/)12G>6WQ.CCPE?AT*E4ZQBI>P]-UNPASSB].V.,KGDU"G$3G]\['UE$3\W M#AWF?5TWMX$$P^ 7[DQ'UWX1;OENY)O<,WW<[SF<>Z_.OI\W#[[K6>_ MS_MZEYJ;Y31W8"+UYM/,W4K'$0H.4+JQ9R-"U^R3V-#&1'4:\&RR"Q@7#L2( M>\.DR,SL/9L.F :/L:B)A@/5.PH4[A@_O>/]^GW/;-G%[:XXR+VZ<8]W[_'A MI(WM1[A:(4?PI>?$'NS#4:\5ZRL7!-VX^,>D'W[8MG6[D&41PX\)X+RK?%=( M'^,K(#E /TYOP.,=+Y-[6GG>EP=5765=4-&"_5IA_=CSY"7W,QO(WZ](/R;B M%S&>WG;8&4DQ7/ATDGJ(2.0:J!MW\_F61PQ?V_VS\LQ%7X@!/IWUYIZ-AF45 M7"T^1*^!F:"AT)6>&UL4$L! A0#% @ MB8E_5ILP'!P8!P 3DD !4 ( !C2 '-A8G,M,C R,S S M,S!?;&%B+GAM;%!+ 0(4 Q0 ( (F)?U:F"2H&5 4 '0W 5 M " =@G !S86)S+3(P,C,P,S,P7W!R92YX;6Q02P$"% ,4 " ") MB7]6%-";N-@8 WD@ $P @ %?+0